PharmacoEconomics - Modern pharmacoeconomics and pharmacoepidemiology (E-Journal) / ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология
Not a member yet
430 research outputs found
Sort by
Сравнение рекомендуемых скрининговых программ в США, Канаде, Нидерландах и Германии
Get PDFThis publication presents a comparison of recommendations of screening programs and prevention activities in the United States, Canada, the Netherlands and Germany for adult non-pregnant population excluding infectious diseases. Sources of funding for such programs and information about their implementation are descripted. According to the search results of the relevant information in open sources, a list of recommended screening programs, as well as the amount of available information describing these programs in foreign countries varies.В данной публикации представлено сравнение рекомендаций скрининговых программ и профилактических мероприятий в США, Канаде, Нидерландах и Германии для взрослого небеременного населения, за исключением инфекционных заболеваний. Рассматриваются источники финансирования таких программ и сведения об их реализации на территории страны. По итогам поиска соответствующей информации в открытых источниках установлено, что в развитых зарубежных странах варьируется как перечень рекомендуемых скрининговых программ, так и объем доступных сведений, описывающих такие программы
АНАЛИЗ ВЛИЯНИЯ НА БЮДЖЕТ ПРИМЕНЕНИЯ БИОЛОГИЧЕСКИХ ПРЕПАРАТОВ В ТЕРАПИИ ВЗРОСЛЫХ ПАЦИЕНТОВ С ЯЗВЕННЫМ КОЛИТОМ И БОЛЕЗНЬЮ КРОНА
Get PDFAims of the study: to assess health care costs of the use of biological agents (vedolizumab and various TNF-α inhibitors) in adult patients with moderate to severe active ulcerative colitis (UC) and moderate or severe active Crohn’s disease (CT) with an unsatisfactory response, loss of response, or intolerance to one or more chemotherapeutic agents, and TNF-α inhibitors.Materials and Methods. Statistical analysis, published reports on inflammatory bowel disease (IBD) treatment, the highest quoted prices of drugs from the list of vital and essential drugs (VED), the size of the maximal wholesale mark-ups, and the regulations of financial expenses in the Russian Federation Health system in 2016, were used in this analysis. Since Vedolizumab has been just recently registered in theRussian Federation and it is yet to be included in the VED, for now the drug has no quoted price. Therefore, we used the price suggested by the manufacturer added with the wholesale markup and VAT.Results. As compared with the biological agents-TNF-α inhibitors currently used in the treatment of adult patients with moderate to severe active UC and moderate to severe active CD who showed an unsatisfactory response, loss of response or intolerance of one or more components of standard therapy, or TNF-α inhibitors, the introduction of Vedolizumab with shares of 3%, 4% and 7% for the first, second and third year is expected to result in cost savings of 26.4 million rubles (0.62%) for UC and 21.5 million rubles (0.63%) for CD
Сравнительный анализ минимизации затрат и влияния на бюджет фиксированных комбинаций ингаляционных глюкокортикостероидов и длительно действующих бета-агонистов для лечения астмы
Get PDFComparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combinations (ICS/LABA) for the treatment of moderate or severe asthma in Russia. Materials andMethods. Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis.Results. The present analysis shows that the 12-month direct medical costs for the treatment of asthma using vilanterol / fluticasone furoate and budesonide / formoterol are 29,276 and 40,447 RUR per patient, respectively. The direct costs of treatment with vilanterol / fluticasone furoate are less than those for budesonide / formoterol by 28%. The annual health budget savings that result from replacing budesonide / formoterol by vilanterol / fluticasone furoate are 1,151,512,731 RUR per 100,000 patients.Conclusion. The present results indicate that the vilanterol / fluticasone furoate FDC is preferable (more beneficial) as compared with the budesonide / formoterol FDC.
Оптимизация расходов не должна убивать людей Итоговый релиз VII Всероссийского Конгресса пациентов
Get PDF.
Клинико-экономический анализ применения комбинированного препарата вилантерол + умеклидиния бромид для терапии хронической обструктивной болезни легких тяжелого и крайне тяжелого течения по сравнению с монотерапией препаратом тиотропия бромид
Get PDFОбзор практики конкретизации программ государственных гарантий и возможные направления по конкретизации Программы государственных гарантий РФ
Get PDFThe article describes questions about State Guarantees fоr free Medical care for Russian Citizen, how they are reflected in existing Programs and changing in the annual revision. Proposed the basic directions of concretization and specified criteria for certain types of medical care. Estimate the positive and negative sides of the proposed reforms.В статье рассмотрены вопросы гарантий оказания гражданам РФ бесплатной медицинской помощи, показано, как они отражаются в существующих программах и как изменяются при ежегодном пересмотре. Предложены основные направления конкретизации, критерии проведения конкретизации для отдельных видов медицинской помощи. Дана оценка положительным и отрицательным сторонам предлагаемых реформ
Фармакоэкономический анализ стоимости антиретровирусных препаратов, применяемых в терапии ВИЧ-инфицированных пациентов
Get PDFThe aim of our study was to conduct a pharmacoeconomic and cost analysis of the therapeutic use of anti-HIV drugs.Material and methods. The study was based on the documented medical histories of HIV-infected patients; it also incorporated the data from the state-sponsored auctions and contracts for drug purchase, as well as the information from the website poisklekarstv.ru with recommendations for Moscow pharmacies. Both statistical and analytical approaches were used.Results. We found that all drugs needed for the treatment of patients with HIV infection are available in Russia. These drugs appear in the updated list of the treatment standards approved for domestic use in Russia.Conclusion. The difference between the government-sponsored prices and the retail prices of these medications has an impact on the costs of ant-HIV therapy
Обзор российских и зарубежных подходов к формированию государственных гарантий бесплатной медицинской помощи
Get PDFThe article reviews national and international publications on various issues of the free healthcare system. We present and discuss recommendations of the UN, the World Health Organization and the International Labor Organization on full coverage of the population with free medical care. В статье рассмотрены российские и международные публикации, касающиеся вопросов оказания гражданам бесплатной медицинской помощи. Рассмотрены рекомендации ООН, Всемирной организации здравоохранения и Международной организации труда по определению подходов к формированию системы всеобщего охвата населения бесплатной медицинской помощью.
РАСПРОСТРАНЕННОСТЬ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ СРЕДИ ПАЦИЕНТОВ АМБУЛАТОРНО-ПОЛИКЛИНИЧЕСКОГО ЗВЕНА В ДАЛЬНЕВОСТОЧНОМ ФЕДЕРАЛЬНОМ ОКРУГЕ
Get PDFThe rapidly growing incidence of obesity and diabetes mellitus, especially in developed countries, stimulates medical experts to closely study the epidemiology of non-alcoholic fatty liver disease (NAFLD). According to the published results of the epidemiological study DIREG 2, the prevalence of NAFLD in outpatients inRussiaincreased over the period from 2007 to 2015 and amounted to 37.3%. In the present report, the population of patients with NAFLD in the Far East Federal District (FEFD) was studied as part of the multicentre epidemiological study DIREG 2.The aim. To analyze the data on FEFD obtained in the DIREG 2 study and compare those with the DIREG 2 data on the entireRussia.Materials and Methods. The prospective disease registry study: epidemiological, observational, cross-sectional, multicentre study on the prevalence of NAFLD in outpatients. The total number of participating patients in FEFD was 2500, including 900 males and 1600 females. Epidemiological data were collected within two routine patient visits to the participating research centers.Results. The major result of this study is that the prevalence of NAFLD in FEFD was significantly lower than that in the entireRussia (21.4% vs 37.3%). Although the rank distribution of the concomitant diseases in FEFD patients was comparable to that in the across-Russia population, the prevalence of metabolic syndrome, menopausal syndrome and hypertriglyceridemia was significantly higher in the FEFD population.Conclusion. Despite the lower prevalence of NAFLD there is a significantly higher prevalence of disorders associated with NAFLD in the FEFD patients as compared with the acrossRussian patients from DIREG2. A set of measures preventing these risk factors from converting into full-scale disease is needed.